RxSight Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 OR For the transition period fromto (Exact Name of Registrant as Specified in its Charter) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☐ Accelerated filer☒Smaller reporting company☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of July 31, 2026, the registrant had 41,593,256 shares of common stock, $0.001 par value per share, outstanding. PART I.FINANCIAL INFORMATIONItem 1.Financial Statements (Unaudited)6Condensed Consolidated Balance Sheets6Condensed Consolidated Statements of Operations and Comprehensive Loss7Condensed Consolidated Statements of Equity8Condensed Consolidated Statements of Cash Flows10Notes to Unaudited Condensed Consolidated Financial Statements11Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations28Item 3.Quantitative and Qualitative Disclosures About Market Risk39Item 4.Controls and Procedures39PART II.OTHER INFORMATIONItem 1.Legal Proceedings40Item 1A.Risk Factors41Item 2.Unregistered Sales of Equity Securities and Use of Proceeds106Item 3.Defaults Upon Senior Securities106Item 4.Mine Safety Disclosures107Item 5.Other Information107Item 6.Exhibits108Signatures110 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS The following discussion and analysis should be read together with our condensed consolidated financial statements and thecondensed notes to those statements included elsewhere in this report. This report contains forward-looking statements within themeaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the SecuritiesExchange Act of 1934, as amended, or the Exchange Act, that are based on our management’s beliefs and assumptions and oninformation currently available to our management. In this report, “we,” “us” and “our” refer to RxSight, Inc., a Delawarecorporation, and its consolidated subsidiaries. Forward-looking statements include, but are not limited to, statements concerning the following: •the sufficiency of our existing capital resources to fund our future operating expenses and capital expenditurerequirements, including our expectation that we do not anticipate the need to raise additional capital or incur additionaldebt in order to reach profitability from operations, provided that we may opportunistically seek to raise capital underadvantageous circumstances from time to time in order to support the expansion of our sales and operations in theUnited States (“U.S.”) and internationally and to pursue other business opportunities;•our belief that our current cash, cash equivalents and short-term investments through the date of filing of this report willbe sufficient to fund our operations for at least the next 12 months;•our expectation that revenue will increase in absolute dollars as we expand our sales organization and sales territories,add customers, expand the base of doctors that are trained to use our products, and expand awareness of our productswith new and existing customers and as doctors perform more procedures using our products;•our belief that selectively increasing the number of sales representatives, practice development personnel and clinicaltrainers will help facilitate further adoptions of our products among existing customer accounts as well as broadenawareness of our products to new accounts;•our plan to grow our business primarily by driving increased utilization of our LAL through heightened awareness ofthe superior clinical outcomes that our RxSight system